Single Dose of Pseudoephedrine Induces Simultaneous Bilateral Acute Angle Closure Crisis

Spencer, Benjamin G; Baskin, Jonathan Z.; Giarola, Blake F; Craig, Jamie E

doi:10.1159/000503854

Cited by 5 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Classic first-generation oral antihistamines and some second-generation oral antihistamines have an anticholinergic effect that induces mydriasis . Pseudoephedrine (a sympathomimetic), which was previously reported as a possible cause of bilateral AAC, was also associated with AAC in our study. Additionally, various mucolytic agents and cough suppressants were associated with AAC.…”

Section: Discussionmentioning

confidence: 99%

“…The major ocular risk factor is a shallow anterior chamber . In addition, several drugs have also been reported to be associated with AAC …”

Section: Introductionmentioning

confidence: 99%

“…5 In addition, several drugs have also been reported to be associated with AAC. [6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24] Understanding the association of drugs with AAC, a disease that can lead to sudden vision loss, is important in preventing the condition. If a patient needs to take a drug that is highly associated with AAC and has demographic and ocular risk factors for this disease, appropriate preventive measures, such as prophylactic laser peripheral iridotomy or cataract surgery, may reduce the risk of AAC occurrence.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Association of Drugs With Acute Angle Closure

Park

2022

JAMA Ophthalmol

View full text Add to dashboard Cite

ImportanceAcute angle-closure (AAC) glaucoma is a sight-threatening disease and can reportedly occur in association with various drugs.ObjectiveTo identify drugs that are associated with AAC glaucoma occurrence and evaluate the risk of AACassociated with each drug.Design, Setting, and ParticipantsA case-crossover study was conducted using the Health Insurance Review and Assessment Service database, which contains medical information of the entire Korean population. Patients who were first diagnosed with AAC and treated between 2013 and 2019 were identified using diagnostic and procedure codes. All drugs that the study participants were prescribed as well as prescription dates during the period of 1 to 180 days before the onset of AAC were extracted from the database. For each patient, 1 to 30 days before onset was considered the hazard period, and 91 to 180 days before AAC onset was considered the control period.Main Outcomes and MeasuresDrugs associated with AAC and odds (calculated as odds ratios [ORs] with 95% CIs) of AAC development associated with each identified drug.ResultsA total of 949 drugs that were prescribed to 13 531 patients with AAC (mean [SD] age, 66.8 [10.6] years; 9585 [70.8%] female) during the period of 1 to 180 days before the onset of AAC were analyzed. A total of 61 drugs were found to be associated with AAC, among which sumatriptan (OR, 12.60 [95% CI, 4.13-38.44]) was associated with the highest odds of AAC development, followed by topiramate (OR, 5.10 [95% CI, 2.22-11.70]) and duloxetine (OR, 4.04 [95% CI, 2.95-5.54]). The median (IQR) period from prescription of the drug to the onset of AAC for the 61 drugs was 11.9 days (10.9-12.8). A number of drugs not previously considered to be associated with AAC, including lactulose (OR, 2.81 [95% CI, 1.72-4.61]) and metoclopramide (OR, 2.52 [95% CI, 1.95-3.25]), were identified.Conclusions and RelevanceResults of this case-crossover study suggest a need to consider AAC risk in patients taking any of the 61 drugs found to be associated with AAC.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The major ocular risk factor is a shallow anterior chamber . In addition, several drugs have also been reported to be associated with AAC …”

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Association of Drugs With Acute Angle Closure

Park

2022

JAMA Ophthalmol

View full text Add to dashboard Cite

show abstract

“…More recently, simultaneous bilateral acute angle-closure crisis (AACC), a sight-threatening ocular emergency, triggered by cold and flu, as well as by preparations containing compounds with sympathomimetic properties [ 112 , 113 ], or by a single oral dose of pseudoephedrine were documented [ 114 ]. The authors point out that the symptoms of simultaneous bilateral AACC may overlap with the flu-like symptoms for which the medications potentially triggering AACC are taken.…”

Section: Ephedra Compoundsmentioning

confidence: 99%

In search of an ideal drug for safer treatment of obesity: The false promise of pseudoephedrine

Munafò

Frara

Perico

et al. 2021

Rev Endocr Metab Disord

View full text Add to dashboard Cite

Obesity is a major public health problem worldwide. Only relatively few treatment options are, at present, available for the management of obese patients. Furthermore, treatment of obesity is affected by the widespread misuse of drugs and food supplements. Ephedra sinica is an old medicinal herb, commonly used in the treatment of respiratory tract diseases. Ephedra species contain several alkaloids, including pseudoephedrine, notably endowed with indirect sympathomimetic pharmacodynamic properties. The anorexigenic effect of pseudoephedrine is attributable primarily to the inhibition of neurons located in the hypothalamic paraventricular nucleus (PVN), mediating satiety stimuli. Pseudoephedrine influences lipolysis and thermogenesis through interaction with β3 adrenergic receptors and reduces fat accumulation through down-regulation of transcription factors related to lipogenesis. However, its use is associated with adverse events that involve to a large extent the cardiovascular and the central nervous system. Adverse events of pseudoephedrine also affect the eye, the intestine, and the skin, and, of relevance, sudden cardiovascular death related to dietary supplements containing Ephedra alkaloids has also been reported. In light of the limited availability of clinical data on pseudoephedrine in obesity, along with its significantly unbalanced risk/benefit profile, as well as of the psychophysical susceptibility of obese patients, it appears reasonable to preclude the prescription of pseudoephedrine in obese patients of any order and degree.

show abstract

Guaifenesin/pseudoephedrine

2020

Reactions Weekly

View full text Add to dashboard Cite

Single Dose of Pseudoephedrine Induces Simultaneous Bilateral Acute Angle Closure Crisis

Cited by 5 publications

References 10 publications

Association of Drugs With Acute Angle Closure

Association of Drugs With Acute Angle Closure

In search of an ideal drug for safer treatment of obesity: The false promise of pseudoephedrine

Guaifenesin/pseudoephedrine

Contact Info

Product

Resources

About